a) pClasper

The pClasper system, invented in Professor Ruddle's laboratory at Yale University, is based on a unique yeast-bacteria shuttle vector specifically designed to clone and modify large inserts by recombination targeting methods in yeast (US Patent #'s 5,866,404; 5,972,614; 6,221,588 and other pending US and foreign patent applications).  These DNA fragments can be rapidly cloned and modified by exploiting the natural recombinogenic nature of yeast cells.  The modified clones can then be shuttled to bacteria for further modification, analysis and the production of large quantities of DNA for the purpose of generating transgenic mice

b) Multiplex Gene Regulation (MGR)

This patented technology, also invented in Professor Ruddles laboratory at Yale University, is exclusively licensed to AGS.  The first binary transgenic system based on viral transactivators and immediate-early enhancers, MGR was developed as a means to study phenotypes generated by potentially lethal genes (US Patent # 5,221,778).  The multiplex system allows the creation of transgenic mouse lines that exhibit precisely regulated and inducible transgene expression.  AGS intends to incorporate a variety of multiplexing options into its transgenic services and product portfolio.

Regulatory Element Library -there is a strong, recent emphasis on the identification of genetic regulatory elements, with the increasing realization that variations in gene regulation contribute extensively to differences in gene expression.  The library of elements that AGS will generate will be unique and useful to drug researchers and developers alike.  Moreover, the enhancer elements that are identified can be linked to reporter genes, to recombinases or to other target genes to create uniquely useful research tools and to expand the range of transgenic mouse models available for academic and industrial clients.  In short, a proprietary collection of regulatory sequences with distinct spatial and temporal specificity will be an invaluable biological resource that will move AGS to the next level of transgenic capability.